184 related articles for article (PubMed ID: 12492731)
1. Systematic review: serotonergic modulators in the treatment of irritable bowel syndrome--influence on psychiatric and gastrointestinal symptoms.
Kilkens TO; Honig A; Rozendaal N; Van Nieuwenhoven MA; Brummer RJ
Aliment Pharmacol Ther; 2003 Jan; 17(1):43-51. PubMed ID: 12492731
[TBL] [Abstract][Full Text] [Related]
2. Serotonergic modulators in the treatment of irritable bowel syndrome: influence on psychiatric and gastrointestinal symptoms.
Castle MZ; Silk DB; Libby GW
Aliment Pharmacol Ther; 2003 Jun; 17(11):1425. PubMed ID: 12786637
[No Abstract] [Full Text] [Related]
3. Alosetron in irritable bowel syndrome.
McColl KE
Lancet; 2000 Jul; 356(9224):164-5. PubMed ID: 10963271
[No Abstract] [Full Text] [Related]
4. Selective 5-hydroxytryptamine antagonism: a role in irritable bowel syndrome and functional dyspepsia?
Maxton DG; Morris J; Whorwell PJ
Aliment Pharmacol Ther; 1996 Aug; 10(4):595-9. PubMed ID: 8853764
[TBL] [Abstract][Full Text] [Related]
5. Serotonin receptor modulation in irritable bowel syndrome: one step forwards and one step backwards.
Whorwell PJ
Gut; 2001 May; 48(5):596-7. PubMed ID: 11302953
[No Abstract] [Full Text] [Related]
6. Effect of alosetron on left colonic motility in non-constipated patients with irritable bowel syndrome and healthy volunteers.
Clemens CH; Samsom M; Van Berge Henegouwen GP; Fabri M; Smout AJ
Aliment Pharmacol Ther; 2002 May; 16(5):993-1002. PubMed ID: 11966509
[TBL] [Abstract][Full Text] [Related]
7. Effects of alosetron on gastrointestinal transit time and rectal sensation in patients with irritable bowel syndrome.
Thumshirn M; Coulie B; Camilleri M; Zinsmeister AR; Burton DD; Van Dyke C
Aliment Pharmacol Ther; 2000 Jul; 14(7):869-78. PubMed ID: 10886042
[TBL] [Abstract][Full Text] [Related]
8. 5-HT4 receptor antagonism in irritable bowel syndrome: effect of SB-207266-A on rectal sensitivity and small bowel transit.
Houghton LA; Jackson NA; Whorwell PJ; Cooper SM
Aliment Pharmacol Ther; 1999 Nov; 13(11):1437-44. PubMed ID: 10571599
[TBL] [Abstract][Full Text] [Related]
9. Effect of alosetron on responses to colonic distension in patients with irritable bowel syndrome.
Delvaux M; Louvel D; Mamet JP; Campos-Oriola R; Frexinos J
Aliment Pharmacol Ther; 1998 Sep; 12(9):849-55. PubMed ID: 9768527
[TBL] [Abstract][Full Text] [Related]
10. Alosetron relieves pain and improves bowel function compared with mebeverine in female nonconstipated irritable bowel syndrome patients.
Jones RH; Holtmann G; Rodrigo L; Ehsanullah RS; Crompton PM; Jacques LA; Mills JG
Aliment Pharmacol Ther; 1999 Nov; 13(11):1419-27. PubMed ID: 10571597
[TBL] [Abstract][Full Text] [Related]
11. Serotonergic modulation of visceral sensation: lower gut.
Camilleri M
Gut; 2002 Jul; 51 Suppl 1(Suppl 1):i81-6. PubMed ID: 12077074
[TBL] [Abstract][Full Text] [Related]
12. Alosetron, a 5-HT3 receptor antagonist, delays colonic transit in patients with irritable bowel syndrome and healthy volunteers.
Houghton LA; Foster JM; Whorwell PJ
Aliment Pharmacol Ther; 2000 Jun; 14(6):775-82. PubMed ID: 10848662
[TBL] [Abstract][Full Text] [Related]
13. Review article: clinical pharmacology of alosetron.
Gunput MD
Aliment Pharmacol Ther; 1999 May; 13 Suppl 2():70-6. PubMed ID: 10429744
[TBL] [Abstract][Full Text] [Related]
14. [Irritable bowel syndrome--role of motility inhibitors].
Holtmann G; Gschossmann J; Kruis W
Internist (Berl); 2001 Apr; 42(4):524-32. PubMed ID: 11326735
[No Abstract] [Full Text] [Related]
15. A double-blind, randomized, placebo-controlled dose-ranging study to evaluate the efficacy of alosetron in the treatment of irritable bowel syndrome.
Bardhan KD; Bodemar G; Geldof H; Schütz E; Heath A; Mills JG; Jacques LA
Aliment Pharmacol Ther; 2000 Jan; 14(1):23-34. PubMed ID: 10632642
[TBL] [Abstract][Full Text] [Related]
16. Alosetron (Lotronex) for treatment of irritable bowel syndrome.
Med Lett Drugs Ther; 2000 Jun; 42(1081):53-4. PubMed ID: 10872030
[No Abstract] [Full Text] [Related]
17. [Soon one "female distress" less. Irritable bowel syndrome responds to serotonin blockers].
MMW Fortschr Med; 2000 Sep; 142(37):55. PubMed ID: 11026224
[No Abstract] [Full Text] [Related]
18. The effect of the 5-HT3 receptor antagonist, alosetron, on brain responses to visceral stimulation in irritable bowel syndrome patients.
Mayer EA; Berman S; Derbyshire SW; Suyenobu B; Chang L; Fitzgerald L; Mandelkern M; Hamm L; Vogt B; Naliboff BD
Aliment Pharmacol Ther; 2002 Jul; 16(7):1357-66. PubMed ID: 12144587
[TBL] [Abstract][Full Text] [Related]
19. Pilot study of the efficacy of renzapride on gastrointestinal motility and symptoms in patients with constipation-predominant irritable bowel syndrome.
Tack J; Middleton SJ; Horne MC; Piessevaux H; Bloor JS; Meyers NL; Palmer RM
Aliment Pharmacol Ther; 2006 Jun; 23(11):1655-65. PubMed ID: 16696817
[TBL] [Abstract][Full Text] [Related]
20. Alosetron improves quality of life in women with diarrhea-predominant irritable bowel syndrome.
Watson ME; Lacey L; Kong S; Northcutt AR; McSorley D; Hahn B; Mangel AW
Am J Gastroenterol; 2001 Feb; 96(2):455-9. PubMed ID: 11232690
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
